Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have histologically-confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer. Enrollment of patients with clear cell histology is encouraged.~* Have measurable disease according to RECIST or detectable disease by 1) CA-125 at least twice the ULN within 14 days prior to registration for protocol therapy; 2) Ascites and/or pleural effusion attributed to tumor; 3) solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST definitions for target lesions.~* Have failed at least one prior platinum based chemotherapeutic regimen.~* No more than 3 prior treatment regimens for epithelial ovarian cancer.~* Prior radiation therapy is allowed to \< 25% of the bone marrow.~* Be at least 4 weeks since last anti-cancer treatment, radiation or surgery at the time of registration for protocol therapy.~* No active cancer in addition to the epithelial ovarian cancer within the last 5 years, with the exception of: superficial skin cancer (basal cell or squamous cell skin carcinoma; carcinoma in situ of the cervix; Stage I endometrial cancer with less than 50% invasion of the myometrium, or other adequately treated Stage I or II cancer in complete remission.~* Age \> 18 years at the time of consent~* Written informed consent and HIPAA authorization for release of personal health information.~* Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 90 days after treatment discontinuation~* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.~Exclusion Criteria:~* No known or suspected allergy to sorafenib or any agent given in the course of this trial.~* No prior treatment with anti-angiogenesis therapy.~* No active CNS metastases.~* No treatment with any investigational agent within 30 days prior to being registered for protocol therapy.~* No concurrent combination anti-retroviral therapy for the treatment of immunodeficiency.~* No clinically significant infections requiring antibiotic treatment.~* No evidence of bowel obstruction, malabsorption, or other contraindication to oral medication.~* No serious non-healing wound, ulcer, or bone fracture.~* No major surgery, open biopsy or significant traumatic injury within 28 days of registration for protocol therapy.~* No use of St. John's Wort or rifampin (rifampicin) while on protocol therapy.~* No condition that impairs patient's ability to swallow whole pills.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: EXPERIMENTAL): Topotecan 3.5 mg/m\^2 + Sorafenib dose escalation:
- Phase II (Type: EXPERIMENTAL): Topotecan 3.5 mg/m\^2 + Sorafenib 400 mg po daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).